Brooklyn Z Score

BTX
 Stock
  

USD 0.57  0.03  5.00%   

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Continue to Brooklyn Immunotherapeuti Piotroski F Score and Brooklyn Immunotherapeuti Valuation analysis.
  
Refresh
Brooklyn Immunotherapeuti Market Capitalization is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Market Capitalization of 217.02 Million in 2021. Working Capital is likely to rise to about 16.3 M in 2022, whereas Capital Expenditure is likely to drop (166.2 K) in 2022. Brooklyn Immunotherapeuti Direct Expenses is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Direct Expenses of 442,750 in 2021. Cost of Revenue is likely to rise to about 9.2 M in 2022, whereas Consolidated Income is likely to drop (125.5 M) in 2022.

Brooklyn Z Score Analysis

Brooklyn Immunotherapeuti's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
 2021 2022 (projected)
Receivables4.6 K4.72 K
Inventories900923.68
Z Score 
 = 
Sum Of  
 
5 Factors 
More About Z Score | All Equity Analysis

Current Brooklyn Immunotherapeuti Z Score

    
  3.2  
Most of Brooklyn Immunotherapeuti's fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Brooklyn Immunotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
First Factor
 = 
1.2 * (
Working Capital
/
Total Assets )
Second Factor
 = 
1.4 * (
Retained Earnings
/
Total Assets )
Thrid Factor
 = 
3.3 * (
EBITAD
/
Total Assets )
Fouth Factor
 = 
0.6 * (
Market Value of Equity
/
Total Liabilities )
Fifth Factor
 = 
0.99 * (
Revenue
/
Total Assets )

Brooklyn Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Brooklyn Immunotherapeuti is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Z Score. Since Brooklyn Immunotherapeuti's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Brooklyn Immunotherapeuti's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Brooklyn Immunotherapeuti's interrelated accounts and indicators.
To calculate Z-Score one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. Z-Score can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition

In accordance with the company's disclosures, Brooklyn Immunotherapeutics has a Z Score of 3.2. This is 52.59% lower than that of the Healthcare sector and 4.19% lower than that of the Biotechnology industry. The z score for all United States stocks is 63.3% higher than that of the company.

Brooklyn Immunotherapeuti Current Valuation Drivers

We derive many important indicators used in calculating different scores of Brooklyn Immunotherapeuti from analyzing Brooklyn Immunotherapeuti's financial statements. These drivers represent accounts that assess Brooklyn Immunotherapeuti's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Brooklyn Immunotherapeuti's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(210.27 K)(582.15 K)(212.89 K)(374.41 K)(430.57 K)(464.56 K)
Revenue Per Employee36.4 K63.14 K63.91 K33.11 K38.08 K52.38 K
Average Assets17.55 M15.62 M15.29 M9.16 M39.31 M42.41 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA1.8 M2.83 M1.4 M(26.43 M)(121.84 M)(125.05 M)
Earnings Before Interest Taxes and Depreciation Amortization USD1.8 M2.83 M1.4 M(26.43 M)(121.84 M)(125.05 M)
Earnings before Tax(1.01 M)(323 K)(2.02 M)(26.53 M)(122.3 M)(125.52 M)
Average Equity5.86 M6.39 M6.2 M(1.33 M)12.58 M13.57 M
Enterprise Value11.7 M6.81 M10.23 M8.31 M195.87 M211.33 M
Free Cash Flow(903 K)(214 K)1.65 M(8.14 M)(23.64 M)(24.26 M)
Invested Capital5.39 M9.38 M8.24 M9.88 M12.45 M11.36 M
Invested Capital Average5.34 M8.47 M11.74 M5.76 M10.43 M9.75 M
Market Capitalization10.61 M5.6 M6.38 M6.64 M217.02 M234.16 M
Tangible Asset Value14.11 M12.18 M11.51 M11.73 M30.39 M24.28 M
Working Capital(1.11 M)2.76 M(25 K)(1.39 M)15.09 M16.28 M

Brooklyn Immunotherapeuti Institutional Holders

Institutional Holdings refers to the ownership stake in Brooklyn Immunotherapeuti that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Brooklyn Immunotherapeuti's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Brooklyn Immunotherapeuti's value.
Security TypeSharesValue
Armistice Capital LlcCommon Shares5.5 M11.3 M
Blackrock IncCommon Shares2.4 M4.9 M
Cypress Point Wealth Management LlcCommon Shares1.9 M3.9 M
Naviter Wealth LlcCommon Shares1.6 M3.2 M
Vanguard Group IncCommon Shares1.3 M2.6 M
Inverness Counsel LlcCommon Shares1.2 M2.5 M
Jpmorgan Chase CoCommon Shares822.2 K1.7 M
Citadel Advisors LlcCall Options108.7 K223 K

Brooklyn Fundamentals

About Brooklyn Immunotherapeuti Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Brooklyn Immunotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brooklyn Immunotherapeuti using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brooklyn Immunotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York. Brooklyn Immunotherapeuti operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 10 people.

Brooklyn Immunotherapeuti Investors Sentiment

The influence of Brooklyn Immunotherapeuti's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Brooklyn. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Brooklyn Immunotherapeuti Implied Volatility

    
  0.0  
Brooklyn Immunotherapeuti's implied volatility exposes the market's sentiment of Brooklyn Immunotherapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Brooklyn Immunotherapeuti's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Brooklyn Immunotherapeuti stock will not fluctuate a lot when Brooklyn Immunotherapeuti's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Brooklyn Immunotherapeuti in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Brooklyn Immunotherapeuti's short interest history, or implied volatility extrapolated from Brooklyn Immunotherapeuti options trading.

Current Sentiment - BTX

Brooklyn Immunotherapeuti Investor Sentiment

Greater number of Macroaxis users are currently bullish on Brooklyn Immunotherapeutics. What is your opinion about investing in Brooklyn Immunotherapeutics? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Continue to Brooklyn Immunotherapeuti Piotroski F Score and Brooklyn Immunotherapeuti Valuation analysis. Note that the Brooklyn Immunotherapeuti information on this page should be used as a complementary analysis to other Brooklyn Immunotherapeuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for Brooklyn Stock analysis

When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
33 M
Return On Assets
-0.74
Return On Equity
-156.16
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.